Amgen Inc. (4AMGN.TI)
TLO - TLO Delayed price. Currency in EUR
Add to watchlist
At close: 03:33PM CEST
| Previous close | 276.55 |
| Open | 249.95 |
| Bid | 274.75 x N/A |
| Ask | 282.50 x N/A |
| Day's range | 249.95 - 284.55 |
| 52-week range | 200.20 - 284.55 |
| Volume | |
| Avg. volume | 53 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.60 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireFDA APPROVES BLINCYTO® (BLINATUMOMAB) IN CD19-POSITIVE PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL) IN THE CONSOLIDATION PHASE
Amgen (NASDAQ:AMGN) today announced the U.S. Food and Drug Administration (FDA) has approved BLINCYTO® (blinatumomab) for the treatment of adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase, regardless of measurable residual disease (MRD) status.
ZacksAmgen (AMGN) Stock Sinks As Market Gains: What You Should Know
The latest trading day saw Amgen (AMGN) settling at $298.50, representing a -0.86% change from its previous close.
Investor's Business DailyWhy It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocks
There hasn't been a new COPD treatment in years. But Regeneron stock analysts are closely watching a pair of key FDA decisions.
© 2024 Yahoo. All rights reserved.